Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes
Article first published online: 29 OCT 2007
Copyright © 2007 John Wiley & Sons, Ltd.
Diabetes/Metabolism Research and Reviews
Volume 24, Issue 1, pages 3–13, January 2008
How to Cite
Raskin, P. (2008), Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. Diabetes Metab. Res. Rev., 24: 3–13. doi: 10.1002/dmrr.783
- Issue published online: 11 DEC 2007
- Article first published online: 29 OCT 2007
- Manuscript Accepted: 22 AUG 2007
- Manuscript Received: 25 JUL 2007
- Novo Nordisk
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.